Presence of tumoural C-reactive protein correlates with progressive prostate cancer (original) (raw)

Basic Research

Prostate Cancer and Prostatic Diseases volume 14, pages 122–128 (2011)Cite this article

Subjects

Abstract

C-reactive protein (CRP) is an acute phase protein implicated in the progression of cancer. A positive correlation between tumour stage and plasma CRP levels was demonstrated in prostate cancer, indicating a relationship between raised CRP levels and more aggressive disease, suggesting a role for inflammatory response in tumour progression. Aim of this study was to assess the tumoural presence and cellular location of CRP and establish if these are linked to clincopathological features of the cohort and patient survival. Tissue microarray technology was employed to analyse 50 matched pairs of hormone sensitive and refractory prostate cancers. Immunohistochemistry was performed using antibody to CRP. CRP was assessed using the weighted histoscore method. CRP presence was observed in the cytoplasm and nucleus of selected tumours. Cytoplasmic CRP correlated positively with metastases at diagnosis (_P_=0.039), whereas nuclear CRP presence correlated with metastases at relapse (_P_=0.006). A trend towards an increase in cytoplasmic and nuclear CRP presence from hormone sensitive to hormone refractory tumours was noticed. No significant association between tumoural CRP presence, time to biochemical relapse or disease-specific survival was observed. Tumoural CRP is likely to have a role in progression of prostate cancer, as it is associated with increased presence of metastases at the time of diagnosis and time of relapse. A larger powered study is necessary to establish if CRP presence is associated with disease-specific survival.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 6 print issues and online access

$259.00 per year

only $43.17 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Cancer Research UK: CancerStats Key Facts on Prostate Cancer. 2010. http://info.cancerresearchuk.org/cancerstats/types/prostate/mortality.
  2. CG58 Prostate cancer: full guidance. 2010. http://www.nice.org.uk/Guidance/CG58/PublicInfo/pdf/English.
  3. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68: 6762–6769.
    Article CAS PubMed PubMed Central Google Scholar
  4. Pepys MB, Hirschfield GM . C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805–1812.
    Article CAS PubMed PubMed Central Google Scholar
  5. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 2007; 12: 252–265.
    Article PubMed Google Scholar
  6. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008; 112: 2377–2383.
    Article CAS PubMed Google Scholar
  7. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC . Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006; 77: 127–129.
    Article CAS PubMed Google Scholar
  8. Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C . Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 2005; 68: 2103–2110.
    Article CAS PubMed Google Scholar
  9. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM . The role of HER1-HER4 and EGFRvIII in hormone-castrate resistant prostate cancer. Clin Cancer Res 2006; 12: 123–130.
    Article CAS PubMed Google Scholar
  10. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ . Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20: 4188–4197.
    Article CAS Google Scholar
  11. Li Q, Withoff S, Verma IM . Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 2005; 26: 318–325.
    Article PubMed Google Scholar
  12. Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y, Sugimachi K . Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus—significance as a tumor marker. Cancer Lett 2003; 192: 89–95.
    Article CAS PubMed Google Scholar
  13. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006; 48: 787–794.
    Article CAS PubMed Google Scholar
  14. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG . C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005; 95: 961–962.
    Article CAS PubMed Google Scholar
  15. Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM et al. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am J Pathol 2009; 175: 1389–1397.
    Article CAS PubMed PubMed Central Google Scholar
  16. Erin N, Wang N, Xin P, Bui V, Weisz J, Barkan GA et al. Altered gene expression in breast cancer liver metastases. Int J Cancer 2009; 124: 1503–1516.
    Article CAS PubMed Google Scholar
  17. Koo JS, Jung W, Jeong J . Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori 2010; 96: 424–432.
    Article PubMed Google Scholar
  18. Nozoe T, Mori E, Takahashi I, Ezaki T . Preoperative elevation of serum C-reactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today 2008; 38: 597–602.
    Article CAS PubMed Google Scholar
  19. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA . The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 2004; 91: 541–543.
    Article CAS PubMed PubMed Central Google Scholar
  20. McArdle PA, McMillan DC, Sattar N, Wallace AM, Underwood MA . The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease. Br J Cancer 2004; 91: 1755–1757.
    Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

This study was supported by the Glasgow Royal Infirmary Endowment Grant.

Author information

Authors and Affiliations

  1. Department of Pathology, Western Infirmary, McGregor Building, Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
    B Elsberger, L Lankston, D C McMillan & J Edwards
  2. Department of Urology, Glasgow Royal Infirmary, Glasgow, UK
    M A Underwood

Authors

  1. B Elsberger
  2. L Lankston
  3. D C McMillan
  4. M A Underwood
  5. J Edwards

Corresponding author

Correspondence toJ Edwards.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

About this article

Cite this article

Elsberger, B., Lankston, L., McMillan, D. et al. Presence of tumoural C-reactive protein correlates with progressive prostate cancer.Prostate Cancer Prostatic Dis 14, 122–128 (2011). https://doi.org/10.1038/pcan.2011.5

Download citation

Keywords

This article is cited by